For research use only. Not for therapeutic Use.
EMA401（Cat No.:I001221）is a potent, selective angiotensin II type 2 receptor (AT2R) antagonist developed for the treatment of neuropathic pain. By blocking AT2R, EMA401 reduces pain signaling without affecting blood pressure, unlike angiotensin type 1 receptor antagonists. It has shown promising results in clinical trials for conditions such as post-herpetic neuralgia and diabetic neuropathy, providing effective pain relief without central nervous system side effects. EMA401 represents a novel approach to pain management, targeting peripheral pain mechanisms and offering hope for patients suffering from chronic neuropathic pain where conventional treatments have limited efficacy.
| Catalog Number | I001221 |
| CAS Number | 1316755-16-4 |
| Molecular Formula | C32H29NO5 |
| Purity | ≥95% |
| Target | target: AT2R |
| Solubility | DMSO ≥ 34mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | (3S)-2-(2,2-diphenylacetyl)-6-methoxy-5-phenylmethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid |
| InChI | InChI=1S/C32H29NO5/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22/h2-18,27,29H,19-21H2,1H3,(H,35,36)/t27-/m0/s1 |
| InChIKey | GHBCIXGRCZIPNQ-MHZLTWQESA-N |
| SMILES | COC1=C(C2=C(CN([C@@H](C2)C(=O)O)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4)C=C1)OCC5=CC=CC=C5 |
| Reference | <p style=/line-height:25px/> <br>[2]. Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. <br>[3]. Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. </p> |
